VKV. O. Korshenko

V. O. Korshenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


V. O. Korshenko has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RESEARCH AND ANALYSIS OF PHENOLIC COMPOUNDS IN ERIGERON ANNUUS FLOWERS FOR USE IN DENTISTRY

    by S.V. Kovalev, A.R. Golovach, N.M. Deviatkina, V.M. Dvornyk, V.I. Volochai, N.O. Vlasenko, V.M. Kovalev, D.V. Karamyshev, V.O. Korshenko

    In the modern medical industry, there is a tendency to increase the share of herbal medicines in the global market of medicines, which is due to certain advantages of herbal medicines compared to synthetic ones. Herbal medicines are inferior to synthetic medicines in terms of effectiveness and potency, they are more economically advantageous, they are used for a long time, have low toxicity and almost have no side effects. Plants affect inflammation of the gums or oral mucosa, reduce toothache and are used for other pathologies of the oral cavity. When medicinal plants are used in dentistry, they exhibit the following therapeutic effects, such as antiseptic, antibacterial, antimicrobial, antiproliferative, antifungal, antioxidant, and antiviral, directly or indirectly.Flavonoids and phenolic acids constitute one of the most abundant groups of plant phenolic compounds. Due to the importance of the content of phenolic compounds for human and plant health, it is necessary to investigate the concentration of flavonoids and phenolic compounds to determine their potential as therapeutic agents and quality control of medicinal plants. Throughout life, a person consumes plants and herbs that contain thousands of flavonoid and phenolic acid components. The genus Erigeron, family Asteraceae, includes about 400 species. Erígeron ánnuus, (Phalacrolóma ánnuum) is an annual herbaceous plant, a species of the genus Small-petaled plant of the Compositae family. An invasive species originating from North America; was brought to Europe, where it spread very widely. HPLC-DAD determined the composition and content of flavonoids and hydroxycinnamic acids in the flowers of Erigeron annuus L. HPLC-DAD revealed 13 phenolic compounds, namely 5 flavonoids (rutin, neohesperidin, luteolin, naringenin, kaempferol) and 8 hydroxycinnamic acids (chlorogenic acid, syringic acid, benzoic acid, p-coumaric acid, trans-ferulic acid, sinapic acid, quinic acid, trans-cinnamic acid). The quantitative determination indicated that the main hydroxycinnamic acids are chlorogenic acid 1081.7 μg/g and sinapic acid 638,2 μg/g. neohesperidin 3433.64 μg/g, kaempferol 1713.88 μg/g, luteolin 1668.47 μg/g were the main flavonoids.

  • Open Access

    Current trends in the standardization of the quality for phytochemical-directed medicinal products

    by N. M. Devyatkina, S. V. Kovalev, V. I. Volochai, D. V. Karamyshev, V. O. Korshenko, N. O. Vlasenko, J. P. Kundiy

    The article discusses theoretical and practical aspects of standardization of medicinal products in pharmacy. The concept of standardization in pharmacy and its purpose, which is to ensure stable quality, safety and effectiveness of medicines, are considered. The importance of the regulatory framework in the process of standardization of medicinal products is emphasized. Examples of regulatory documents (Pharmacopoeias, state and international standards), such as the European Pharmacopoeia (Ph. Eur.)), the US Pharmacopeia (USP), the World Health Organization (WHO) Guidelines, are given. Aim. To determine and provide a comprehensive approach of the features of the drug standardization from the perspective of pharmacognosy, taking into account the principles of pharmacy and pharmacology. Materials and methods. The materials of the study were the publications of representatives of the domestic pharmacognostic doctrine and the works of foreign scientists. Regulatory documents at the level of the countries of the European Union, the USA, and the WHO have been analyzed. These documents include the European Pharmacopoeia (Ph. Eur.), Monograph 2034 “Herbal Drug Preparations”, the US Pharmacopeia (USP), three regulations (law-making acts) – the WHO Technical Report Series No.1010 (2018), the WHO Guidelines on Good Manufacturing Practices (GMP) for Herbal Medicines and the WHO Guidelines for assessing the quality of herbal medicines with reference to contaminants and residues, which are guiding for use in all member countries of the WHO. Results. The peculiarities of the drug standardization through the prism of the science of pharmacognosy, as well as related sciences, such as pharmaceuticals and pharmacology, have been determined. It has been found that current standardization trends involve the introduction of innovative technologies, in particular biotechnological methods, pharmacogenomics and artificial intelligence. It has been determined that the standardization of medicinal products can be called a multicomponent process, which differs depending on the boundaries (the WHO or a specific country and its pharmacopoeia) and the purpose of this process, but has as its ultimate goal the creation of uniform, transparent, open standards before obtaining a marketing authorization for a medicinal product, which takes place exclusively within the framework of the legal field. Conclusions. The standardization of medicinal products is a key process of pharmaceutical control that guarantees their quality, safety and effectiveness. It is based on international and national regulations, such as the European Pharmacopoeia, the US Pharmacopoeia and the WHO Guidelines. Improving standardization methods is the key to increasing the effectiveness and safety of medicines, which, in turn, contributes to improving the quality of medical care.

  • EPIDEMIC PROCESS OF ACUTE INTESTINAL INFECTIONS IN UKRAINE AGAINST THE BACKGROUND OF THE COVID-19 EPIDEMIC

    by T.A. Sergeyeva, Si, Yu.V. Kruglov, N.S. Bugaenko, V.A. Korshenko, L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases of National Academy of Medical Science of Ukraine", Kyiv